Last edition
News about "clinical trial "
Anteris Technologies Global Corp. Begins US Enrollment in PARADIGM Trial for DurAVR Heart Valve
Anteris marks first patients successfully treated in US as global trial evaluates safety and effectiveness of DurAVR THV against existing transcatheter aortic valve therapies.
Clinical Trial | 06/05/2026 | By News Bureau
Cellenkos Receives US FDA IND Clearance for CK0802 Phase 1b/ 2a Trial in GVHD
The US Food and Drug Administration (FDA) clears Cellenkos Inc IND for CK0802, a first-in-class off-the-shelf Treg therapy, advancing to a phase 1b/2a trial in steroid-refractory Graft-Versus-Host Disease (GVHD).
Clinical Trial | 06/05/2026 | By News Bureau
Precision BioSciences Begins Patient Enrollment in Phase 1/2 FUNCTION-DMD Trial
Precision BioSciences activates its first clinical site at Arkansas Children’s Hospital and begins patient enrollment in the phase 1/2 FUNCTION-DMD trial of PBGENE-DMD for Duchenne muscular dystrophy.
Clinical Trial | 30/04/2026 | By News Bureau
Argo Biopharma Doses First Patient in Phase 1 Trial of siRNA Drug BW-50218
Argo Biopharma doses first patient in Phase 1 trial of BW-50218, an siRNA therapeutic from its RADS platform designed for potent, durable gene silencing with targeted hepatic delivery and improved safety.
Clinical Trial | 29/04/2026 | By News Bureau
Meiji Seika Pharma Invests in Centivax for Universal Vaccine Platform
Meiji Seika Pharma invests in Centivax to advance a next-generation universal vaccine platform, with lead candidate Centi-Flu 01 currently in a Phase 1 influenza study.
Clinical Trial | 31/03/2026 | By News Bureau
Endogenex Raises USD 50 Million to Advance Novel Diabetes Treatment
Series C extension led by Arboretum Ventures to fund pivotal clinical study and support regulatory pathway for ReCET System.
Clinical Trial | 26/03/2026 | By News Bureau | 112
Harbour BioMed Publishes Positive Phase I Data for HBM9378 in Immunology
Harbour BioMed reports favourable safety and pharmacokinetic profile for HBM9378 in Phase I trial, supporting further development for severe immunological disorders.
Clinical Trial | 23/03/2026 | By News Bureau
Biotheryx Doses First Patient in Dose Expansion Trial of BTX-9341 for Advanced Breast Cancer
Biotheryx advances BTX-9341 into a dose expansion trial with fulvestrant for HR+/HER2- breast cancer, aiming to overcome resistance in patients previously treated with CDK4/6 inhibitors.
Clinical Trial | 19/03/2026 | By News Bureau | 115
BioVersys AG receives US Food and Drug Administration nod to include US patients in Phase III BV100 trial targeting drug-resistant pneumonia, marking progress in combating deadly hospital infections globally.
Clinical Trial | 18/03/2026 | By News Bureau
Aisa Pharma presented Phase II RECONNOITER trial results showing AISA-021 improved attack-free days and reduced duration of Raynaud’s attacks in systemic sclerosis patients at the World Systemic Sclerosis Congress.
Clinical Trial | 10/03/2026 | By News Bureau
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy